Forma Therapeutics Holdings (FMTX) Tops Q3 EPS by 5c; Reports Cash and Cash Equivalents of $531.8M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Forma Therapeutics Holdings (FMTX) Tops Q3 EPS by 5c; Reports Cash and Cash Equivalents of $531.8M

Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

November 12, 2021 7:05 AM EST

Significant progress achieved on three clinical stage programs focused on rare hematologic diseases and cancers

Etavopivat Phase 1 open label extension enrollment in sickle cell disease (SCD) complete, updated results to be presented at American Society of Hematology (ASH) Annual Meeting December 11-14

Initial Phase 1 results presented in men with metastatic castration-resistant prostate cancer (mCRPC ) showed FT-7051 well-tolerated with evidence of clinical activity

Olutasidenib combination data in relapsed/refractory acute myeloid leukemia (R/R/ AML) to be presented at ASH Annual Meeting December 11-14

... More